Utilization of Single Crystal X-Ray Studies of Process Relevant Pharmaceutical Crystal Forms to Support Qbd

Wednesday, November 19, 2008: 5:00 PM
Washington A Room (Loews Philadelphia Hotel)

John D. DiMarco, Solid State Chemistry, Analytical R&D, Bristol-Myers Squibb, Princeton, NJ
Michael A. Galella, Solid State Chemistry, Analytical R&D, Bristol-Myers Squibb, Princeton, NJ
Raymond P. Scaringe, Solid State Chemistry, Analytical R&D, Bristol-Myers Squibb, Princeton, NJ
Carolyn J. Pommier, Solid State Chemistry, Analytical R&D, Bristol-Myers Squibb, Princeton, NJ
Jack Z. Gougoutas, Solid State Chemistry, Analytical R&D, Bristol-Myers Squibb, Princeton, NJ

Ideally, the active pharmaceutical ingredient has a single well-characterized and relatively stable crystal structure. However, complications can arise for molecules that crystallize in several solvated and/or neat forms which may de-solvate/transform and/or interconvert during manufacturing processes. Single crystal studies of these forms define their structure/composition and moreover allow PXRD simulations and correlation of spectra with structure (Raman, IR) which can be used in the determination of thermodynamic relationships, the mapping of design space, and ultimately to improve process control. Some recent examples will be presented, with emphasis on process relevant forms of dasatinib.
Extended Abstract: File Not Uploaded
See more of this Session: Applications of Chemometrics for Process Development
See more of this Group/Topical: Process Development Division